BioAegis raises $3 million

02/8/2013 | American City Business Journals

A funding round has brought in $3 million for biotech startup BioAegis Therapeutics. The company plans to file an investigational new-drug application with the FDA and launch a Phase IIb/III study of human plasma gelsolin, a natural human protein, in preventing the spread of inflammation resulting in multiple organ dysfunction syndrome in intensive care units.

View Full Article in:

American City Business Journals

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX